Advertisement
U.S. Markets close in 29 mins

Rocket Pharmaceuticals, Inc. (RCKT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.74+0.25 (+1.35%)
As of 03:30PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close18.49
Open18.50
Bid18.68 x 100
Ask18.83 x 100
Day's Range18.17 - 18.92
52 Week Range15.13 - 32.53
Volume436,914
Avg. Volume848,496
Market Cap1.705B
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-2.77
Earnings DateNov 04, 2024 - Nov 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.33
  • Associated Press Finance

    Rocket Pharmaceuticals: Q2 Earnings Snapshot

    CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. RCKT) on Monday reported a loss of $69.6 million in its second quarter. The Cranbury, New Jersey-based company said it had a loss of 74 cents per share.

  • Insider Monkey

    Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?

    Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund declined 2.55% (Institutional Shares) in the quarter compared to a 1.02% decline for the Russell 3000 Health Care Index (benchmark) and a 3.22% gain for the Russell […]

  • Zacks

    FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

    Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.